RCUS Stock Analysis: Buy, Sell, or Hold?
RCUS - Arcus Biosciences, Inc.
$30.33
1.41 (4.88%)
▲
5d:
+0.26%
30d:
+23.95%
90d:
+38.87%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When RCUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RCUS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RCUS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RCUS is currently trading at $30.33, which is considered extended relative to its 30-day fair value range of $23.06 to $28.67.
Technical Outlook: Technically, RCUS is in a uptrend. Immediate support is located at $23.80, while resistance sits at $31.73. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: RCUS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $35.75 (+17.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RCUS is in a uptrend. Immediate support is located at $23.80, while resistance sits at $31.73. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: RCUS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $35.75 (+17.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$23.06 -
$28.67
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- BEARISH: Price extended above range (+5.8% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- BULLISH: Trading below Wall St target ($35.75)
Trading Range Analysis
30-Day Trading Range
$23.06 -
$28.67
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$23.80
Resistance Level
$31.74
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.77
Wall Street Target
$35.75
(+17.9%)
Revenue Growth (YoY)
-39.3%
Profit Margin
-156.4%
Share & Embed Analysis
Last updated: July 03, 2026 4:54 PM ET
Data refreshes hourly during market hours. Next update: 5:54 PM
Data refreshes hourly during market hours. Next update: 5:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Juan C Jaen
SELL
31823 shares
2026-01-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
Advanced RCUS Option Strategies
Professional options setups generated by AI based on today's RCUS price and gamma walls.
